Filing Details
- Accession Number:
- 0001213900-21-029446
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-05-27 06:15:01
- Reporting Period:
- 2021-05-21
- Accepted Time:
- 2021-05-27 06:15:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1158780 | Pluristem Therapeutics Inc | PSTI | Biological Products, (No Disgnostic Substances) (2836) | 980351734 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1810117 | Partnership Limited - Capital Wolf Clover | 24 Bodenhimer Street Tel Aviv, L3 6200838 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-05-21 | 69,838 | $3.98 | 3,818,026 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-24 | 79,300 | $3.83 | 3,738,726 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-25 | 261,238 | $3.84 | 3,477,488 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.78 to $3.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.65 to $4.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
